Neil A Williams Selected Research

E coli heat-labile enterotoxin

9/2008	The B subunit of Escherichia coli heat-labile enterotoxin inhibits Th1 but not Th17 cell responses in established experimental autoimmune uveoretinitis.
2/2006	Protection of non-obese diabetic mice from autoimmune diabetes by Escherichia coli heat-labile enterotoxin B subunit.
7/2002	Modulation of human monocytes by Escherichia coli heat-labile enterotoxin B-subunit; altered cytokine production and its functional consequences.
6/2002	CD8+ T cell apoptosis induced by Escherichia coli heat-labile enterotoxin B subunit occurs via a novel pathway involving NF-kappaB-dependent caspase activation.
6/2002	Escherichia coli heat-labile enterotoxin B subunit prevents autoimmune arthritis through induction of regulatory CD4+ T cells.
6/2002	Modulation of B lymphocyte signalling by the B subunit of Escherichia coli heat-labile enterotoxin.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Neil A Williams Research Topics

Disease

6	Autoimmune Diseases (Autoimmune Disease) 01/2009 - 06/2002
4	Human Influenza (Influenza) 05/2020 - 12/2004
4	Neoplasms (Cancer) 03/2015 - 03/2005
3	Pneumococcal Infections 06/2015 - 08/2011
2	Infections 05/2020 - 06/2015
2	Cholera 01/2004 - 10/2002
1	Tetanus 02/2019
1	Diarrhea 01/2014
1	HIV Infections (HIV Infection) 01/2013
1	Acquired Immunodeficiency Syndrome (AIDS) 01/2012
1	Bruton type agammaglobulinemia 04/2009
1	Type 1 Hyper-IgM Immunodeficiency Syndrome 04/2009
1	Posterior Uveitis 09/2008
1	Renal Cell Carcinoma (Grawitz Tumor) 04/2008
1	Type 1 Diabetes Mellitus (Autoimmune Diabetes) 02/2006
1	Necrosis 07/2002
1	Experimental Arthritis 06/2002
1	Arthritis (Polyarthritis) 06/2002

Drug/Important Bio-Agent (IBA)

7	AntigensIBA 02/2019 - 01/2004
6	E coli heat-labile enterotoxinIBA 09/2008 - 06/2002
5	Proteins (Proteins, Gene)FDA Link 01/2013 - 01/2004
3	Enterotoxins (Enterotoxin)IBA 03/2015 - 10/2002
3	VaccinesIBA 01/2014 - 01/2004
2	Immunologic Factors (Immunomodulators)IBA 07/2002 - 06/2002
1	fucoidanIBA 05/2020
1	Peptides (Polypeptides)IBA 02/2019
1	Membrane Proteins (Integral Membrane Proteins)IBA 03/2015
1	Histocompatibility Antigens Class IIBA 03/2015
1	Carrier Proteins (Binding Protein)IBA 01/2014
1	Immunoglobulin D (IgD)IBA 01/2013
1	Immunoglobulin G (IgG)IBA 01/2013
1	Immunoglobulin M (IgM)IBA 01/2013
1	5-(6)-carboxyfluorescein diacetate succinimidyl ester (CFSE)IBA 01/2012
1	Polysaccharides (Glycans)IBA 12/2011
1	Pneumococcal Vaccines (Pneumococcal Polysaccharide Vaccine)IBA 12/2011
1	Bacterial ToxinsIBA 01/2009
1	Retinaldehyde (Retinal)IBA 09/2008
1	AutoantigensIBA 04/2008
1	Neoplasm Antigens (Tumor Antigens)IBA 04/2008
1	EpitopesIBA 04/2008
1	Hemagglutinins (Hemagglutinin)IBA 04/2008
1	Intercellular Adhesion Molecule-1 (Intercellular Adhesion Molecule 1)IBA 03/2005
1	AntibodiesIBA 12/2004
1	Influenza Vaccines (Influenza Vaccine)FDA Link 12/2004
1	Interferon-gamma (Interferon, gamma)IBA 12/2004
1	Interleukin-5 (Interleukin 5)IBA 12/2004
1	To autoantigenIBA 01/2004
1	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 07/2002
1	InterleukinsIBA 07/2002
1	Interleukin-6 (Interleukin 6)IBA 07/2002

Therapy/Procedure

2	Therapeutics 04/2008 - 01/2004
1	Art Therapy 06/2015
1	Highly Active Antiretroviral Therapy (HAART) 01/2012
1	Tonsillectomy 03/2008
1	Mucosal Administration 06/2002